相关实验视频
Updated: May 27, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.5K
在重症患者中持续监测高血糖:一项随机对照试验
Andrew J Franck1, Andrew L Hendrickson1, Evan D Telford1
1North Florida/South Georgia Veterans Health System, Gainesville, FL.
Chest
|February 16, 2025
概括
与标准监测相比,持续血糖监测器 (CGM) 在危急病患者中没有显著改善血糖控制. 这项研究不支持ICU中常规使用CGM.
科学领域:
- 临界护理医学 临界护理医学
- 内分泌学 在内分泌学.
- 医疗器械 医疗器械
背景情况:
- 持续血糖监测 (CGM) 对重症患者的高血糖管理具有潜在的好处.
- 目前,有限的证据支持在重症监护室 (ICU) 常规使用CGM.
研究的目的:
- 为了评估连续血糖监测器 (CGMs) 是否可以改善与标准护理相比,在患有高血糖症的重症患者的目标血糖范围内的时间.
主要方法:
- 一个由研究者发起的,单中心的,随机对照试验.
- 患有高血糖或糖尿病的成年ICU患者被随机分配到CGM或标准葡萄糖监测.
- 主要结局是时间在正常血糖范围内的百分比 (70-180 mg/dL).
主要成果:
- 八十五名参与者被随机分配 (43名参加CGM,42名参加标准护理).
- 在CGM组 (60.5%) 和标准护理组 (61.4%) 之间,在目标葡萄糖范围内的时间没有发现统计学上显著的差异.
- 除了患者满意度之外,二级结局也没有显著差异.
结论:
- 持续血糖监测 (CGM) 没有显示出在ICU中常规血糖监测的标准护理的优越性.
- 目前的证据不支持基于这项试验为重症患者常规实施CGM.
相关概念视频
Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149
Diabetes: Management and Pharmacotherapy
229
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
229
Diabetes: Symptoms, Diagnosis, and Complications
498
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
498
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Glucose Homeostasis: Regulation of Blood Glucose
1.4K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.4K
Oral Hypoglycemic Agents: Glinides
131
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
131

